We have changed our name from Oncothyreon to Cascadian Therapeutics
Now Enrolling
A Phase 2 trial evaluating ONT-380 vs Placebo in combination with Herceptin™ and Xeloda™ in Patients with Metastatic HER2+ Breast Cancer.
  • Committed to Improving Patients' Lives
  • Innovative Cancer Therapies
Innovative Cancer Therapies - Our pipeline includes ONT-380, a selective small molecule HER2 inhibitor. - Learn More >1 Committed to Improving Patients' Lives - Cascadian Therapeutics is conducting clinical trials in multiple cancer indications. - Learn More >2 Extending Our Reach Through Strategic Partnerships - We leverage partnerships to bring new therapies to more patients, more quickly. - Learn More >3
Phase 2 Clinical Trial Now Enrolling Women with Her2+ Breast Cancer
A Pipeline of Innovative Product Candidates
View Our Clinical Data and Scientific Presentations
Announcements
Now Enrolling
A Phase 2 trial evaluating ONT-380 vs Placebo in combination with Herceptin™ and Xeloda™ in Patients with Metastatic HER2+ Breast Cancer.
Phase 2 Clinical Trial Now Enrolling Women with Her2+ Breast Cancer
A Pipeline of Innovative Product Candidates
View Our Clinical Data and Scientific Presentations